安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark Our purpose is to drive change to defeat diabetes and other serious chronic diseases
- Our medicines | Diabetes medications | Obesity medication - Novo Nordisk
Overview of our diabetes medications, obesity medication and also medicines within haemophilia, human growth hormone and hormone replacement therapy
- Press releases - Novo Nordisk
Novo Nordisk press releases and company announcements DISCLAIMER STATEMENT Novo Nordisk hereby excludes all liability for any claim, loss, demands or damages of any kind whatsoever (whether such claims, loss, demands or damages were foreseeable, known or otherwise) arising out of or in connection with the use of this website or the information, content or materials included on this site
- Investors - Novo Nordisk
Investor Relations information Investor highlights Financial results, events and calendar Annual General Meeting 2026 Annual Report 2025 ESG Share information Investor Portal Bond information Company announcements and press releases Contact Investor Relations
- Who we are - Novo Nordisk
A global healthcare company with more than 90 years of innovation in treatment for serious chronic disease, like diabetes and obesity
- Obesity is not a life choice and losing weight is not simple - Novo Nordisk
Our mission At Novo Nordisk, treating – and ultimately, preventing – obesity is central to our enduring purpose of driving change to defeat serious chronic diseases
- R D pipeline - Novo Nordisk
At Novo Nordisk, our R D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, cardiovascular disease, rare blood and endocrine disorders, and other serious chronic diseases
- Novo Nordisk Annual Report 2025
See our latest Annual Report and other reporting related information
|
|
|